{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125464","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.331841+00:00","generated_at":"2026-05-30T01:29:02.557106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iridex Q3 revenue $11.6M (-10% YoY); net loss $1.9M; expects EBITDA breakeven in Q4","bullets":["Total revenue $11.6M, down 10% YoY; retina revenue $6.5M (-18% YoY).","Cyclo G6 glaucoma revenue $3.1M (+3% YoY) with 13,600 probes sold.","Net loss $1.9M ($0.12/sh) vs $1.8M loss ($0.11/sh) in Q3'23; gross margin 37.3% vs 43.7%.","Appointed Patrick Mercer as CEO (effective Oct 1, 2024); strategic review ongoing with multiple parties.","New Medicare LCDs effective Nov 17, 2024 expected to boost glaucoma product adoption."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125464","json":"https://secwatch.observer/filing/0000950170-24-125464.json","markdown":"https://secwatch.observer/filing/0000950170-24-125464.md","text":"https://secwatch.observer/filing/0000950170-24-125464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017024125464/0000950170-24-125464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017024125464/irix-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:29:02.557106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}